Buprenorphine: all 305 studies that test it

Page 2 of 4. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy VolunteersCompletedNCT01148537Phase 1Results posted
• Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension PhaseCompletedNCT01141283Phase 3Results posted
• A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent IndividualsCompletedNCT01136356Phase 1/2Results posted
• Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension PhaseTerminatedNCT01135524Phase 3Results posted
• Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015TerminatedNCT01125917Phase 3Results posted
• Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)CompletedNCT01075971Phase 2Results posted
• Buprenorphine for Late-Life Treatment Resistant DepressionCompletedNCT01071538Phase 2Results posted
• Study of Buprenorphine HCl Buccal Film in the Treatment of Dental PainCompletedNCT00941304Phase 2Results posted
• Buprenorphine and Methadone for Opioid Dependent Chronic Pain PatientsCompletedNCT00879996Phase 4Results posted
• Relapse Prevention to Reduce HIV Among Women PrisonersCompletedNCT00763958Phase 4Results posted
• Abuse Liability of Suboxone Versus SubutexCompletedNCT00710385Phase 3Results posted
• Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical TrialCompletedNCT00684554Phase 2/3Results posted
• Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)CompletedNCT00684073Phase 4Results posted
• Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/NaloxoneCompletedNCT00637000Phase 2Results posted
• Buprenorphine for PrisonersCompletedNCT00574067Phase 3Results posted
• Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)CompletedNCT00571961Not applicableResults posted
• Buprenorphine as a Treatment in Opiate Dependent Pain PatientsTerminatedNCT00552578Phase 4Results posted
• Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of KneeCompletedNCT00531427Phase 3Results posted
• Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT00490919Phase 3Results posted
• Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/RitonavirCompletedNCT00486330Not applicableResults posted
• Buprenorphine's Dose Response CurveCompletedNCT00460239Phase 2Results posted
• Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee ReplacementTerminatedNCT00403234Phase 2Results posted
• Buprenorphine in the Treatment of Osteoarthritis (OA) in the ElderlyCompletedNCT00324038Phase 4Results posted
• Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.TerminatedNCT00320801Phase 3Results posted
• Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.TerminatedNCT00315458Phase 3Results posted
• The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.CompletedNCT00315445Phase 3Results posted
• Starting Treatment With Agonist Replacement Therapies (START)CompletedNCT00315341Phase 4Results posted
• Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or KneeCompletedNCT00313846Phase 3Results posted
• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back PainTerminatedNCT00313014Phase 3Results posted
• Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA PainCompletedNCT00312572Phase 3Results posted
• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis PainTerminatedNCT00312221Phase 3Results posted
• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant PainCompletedNCT00312195Phase 3Results posted
• RCT Comparing Methadone and Buprenorphine in Pregnant WomenCompletedNCT00271219Phase 3Results posted
• Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug UsersTerminatedNCT00270257Phase 3Results posted
• Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder ArthroscopyActive, not recruitingNCT06742554Phase 4
• Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).TerminatedNCT06406400Phase 1
• Psychopharmacological Treatment of Emotional DistressWithdrawnNCT06133114Phase 4
• Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use DisorderCompletedNCT06086275Phase 1
• Low-dose Versus a High-dose Sublingual Buprenorphine InductionActive, not recruitingNCT05944952Phase 4
• Transdermal Buprenorphine Patch for Laparoscopic CholecystectomyCompletedNCT05871424Not applicable
• Novel Induction to Buprenorphine/NaloxoneTerminatedNCT05644587Phase 4
• True Functional Restoration and Analgesia in Non-Radicular Low Back PainStatus unknownNCT05419297Phase 4
• Extended-release Pharmacotherapy for Opioid Use DisorderCompletedNCT05164549Phase 3
• Role of Preoperative Transdermal Buprenorphine Patch in Reducing Postoperative Opioids Consumption in Patients Undergoing Total Knee Arthroplasties - A Randomised Controlled Trial.Status unknownNCT05042648Phase 4
• Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using BuprenorphineCompletedNCT04991974Phase 2/3
• Buprenorphine Induction for Fentanyl Dependent Opioid UsersWithdrawnNCT04794790Early Phase 1
• Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant PatientsWithdrawnNCT04771689Phase 4
• Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use DisorderWithdrawnNCT04737603Phase 2
• Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)Active, not recruitingNCT04464980Phase 2
• Rapid Antidepressant Improvement Secondary to Excitatory Brain ResponsesCompletedNCT04276259Phase 4
• Anti-suicidal Effects of Buprenorphine in Opioid Use DisorderWithdrawnNCT04234516Phase 4
• Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating WomenWithdrawnNCT04212065Phase 4
• Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder SymptomsWithdrawnNCT04091009Phase 4
• Buprenorphine Transdermal Patches Pharmacokinetic StudyStatus unknownNCT03975010Phase 1
• A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer PainStatus unknownNCT03967327Phase 3
• Community Studies of Long Acting Buprenorphine (CoLAB)Status unknownNCT03809143Phase 3
• Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference PatchCompletedNCT03785613Phase 1
• Medication Maintenance Therapy in Community Pharmacy SettingsCompletedNCT03766893Early Phase 1
• Buprenorphine-Fentanyl Interaction StudyCompletedNCT03747341Phase 1
• Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal SymptomatologyWithdrawnNCT03740243Phase 4
• Buprenorphine for Probationers and Parolees: Bridging the Gap Into TreatmentSuspendedNCT03616236Phase 3
• Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid WithdrawalCompletedNCT03489161Early Phase 1
• Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff RepairCompletedNCT03380533Phase 2/3
• Efficacy of Buprenorphine on Postoperative Endodontic AnalgesiaTerminatedNCT03268278Phase 1
• Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid UseStatus unknownNCT03266445Phase 4
• Intravenous Buprenorphine Versus Morphine for Severe Pain in the Emergency DepartmentStatus unknownNCT03256487Phase 2
• Buprenorphine in the Emergency DepartmentCompletedNCT03174067Phase 4
• High Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics OpioidStatus unknownNCT03156907Phase 2
• Opioid Dependence Treatment Therapies in PregnancyCompletedNCT03098407Not applicable
• Single-dose, Study of RBP-6000 in Opioid Dependent IndividualsCompletedNCT02765867Phase 1
• Effects of Low Dose Buprenorphine on Recovery After Hip or Knee ArthroplastyCompletedNCT02575664Phase 4
• Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use DisorderCompletedNCT02559973Phase 1
• Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal SurgeryCompletedNCT02416804Phase 4
• Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal PainCompletedNCT02372591Phase 1
• Bioequivalence and Adhesion Comparison of Buprenorphine PatchesCompletedNCT02268422Phase 1
• Efficacy of Pain Treatment on Depression in Patients With DementiaCompletedNCT02267057Phase 4
• Incomplete Response in Late-Life Depression: Getting to Remission With BuprenorphineCompletedNCT02263248Phase 1/2
• Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot StudyStatus unknownNCT02249026Phase 1/2
• Butrans for Treatment of Restless Legs SyndromeWithdrawnNCT02138357Phase 4
• Drug Interaction & Methadone & BuprenorphineCompletedNCT02045693Phase 1
• Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous BuprenorphineCompletedNCT01854489Phase 4
• Neurocognitive Effects of Opiate Agonist TreatmentCompletedNCT01733693Phase 4
• Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent SubjectsWithdrawnNCT01713803Phase 3
• Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)CompletedNCT01708707Phase 2
• Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to BenzodiazepinesCompletedNCT01671410Phase 1
• Norspan Transdermal Patches Study in Osteoarthritis PatientsCompletedNCT01643759Phase 1
• Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine MaintenanceCompletedNCT01642030Phase 1
• Buprenorphine in Acute Renal Colic Pain ManagementCompletedNCT01546701Phase 4
• NORSPAN Transdermal Patches Phase III Study In Non-Cancer PainCompletedNCT01476774Phase 3
• Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back PainWithdrawnNCT01431742Phase 3
• Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe PainWithdrawnNCT01324544Phase 3
• Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD PatientsStatus unknownNCT01311570Phase 1
• Efficacy of Buprenorphine for Treatment of Acute PainCompletedNCT01298297Phase 4
• Analgesic and Antihyperalgesic Effects of Morphine and BuprenorphineCompletedNCT01296334Not applicable
• Norspan Efficacy and Safety Among Elderly SubjectsCompletedNCT01276431Phase 4
• Drug-Drug Interaction Study Between Telaprevir and BuprenorphineCompletedNCT01275599Phase 1
• Re-Treatment Study of Probuphine in Opioid AddictionCompletedNCT01262261Phase 3
• HIV Risk Reduction in Subutex Injectors in TbilisiCompletedNCT01131273Phase 3
• A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid AddictionCompletedNCT01114308Phase 3
• Treatment for Opioid Dependent OffendersCompletedNCT01082679Phase 2/3

← Buprenorphine overview